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Received 2 October 2006; received in revised form 21 December 2006; accepted 3 January 2007AbstractEquine herpesvirus 1 (EHV-1) is an important equine pathogen that causes respiratory disease, abortion, neonatal death and
paralysis. Although vaccines are available, they are not fully protective and outbreaks of disease may occur in vaccinated herds.
Therefore, there is an urgent need for effective antiviral treatment. For three abortigenic (94P247, 97P70 and 99P96) and three
neuropathogenic isolates (97P82, 99P136 and 03P37), the effect of acyclovir, ganciclovir, cidofovir, adefovir, 9-(2-phospho-
nylmethoxyethyl)-2,6-diaminopurine (PMEDAP) and foscarnet on plaque number was studied. Additionally, for isolate 97P70,
the effect on plaque size was investigated. Ganciclovir was most potent in reducing plaque number, followed by PMEDAP and
acyclovir. Adefovir and cidofovir were less effective and foscarnet was the least effective compound. There were no differences
detected for acyclovir, ganciclovir, adefovir and PMEDAP between the abortigenic and neuropathogenic isolates. One
abortigenic isolate (99P96) was more susceptible to cidofovir and two neuropathogenic isolates (99P136 and 03P37) were
less susceptible to foscarnet. For isolate 97P70, all compounds resulted in a significant reduction of plaque size. The most
remarkable effect was observed for cidofovir. It was 40-fold more effective in reducing plaque size than in reducing plaque
number. In conclusion, ganciclovir was the most potent compound and therefore, may be a valuable candidate for the treatment
of EHV-1 infections in horses. The antiviral effect of foscarnet on plaque number was highly dependent on the viral isolate
tested. Therefore, it is no valuable antiviral for the treatment of herpesvirus-infections. Cidofovir, although less effective in
reducing plaque number, had a strong effect on plaque size.
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Equine herpesvirus 1 (EHV-1), a member of the
Alphaherpesvirinae, is a major pathogen of horses.
The virus is endemic worldwide and most horses
become infected during their first year of life (Ostlund,
1993). After exposure, EHV-1 replicates in the upper
respiratory tract. This can be associated with respiratory
disorders, characterised by fever, anorexia, nasal
discharge of varying severity and ocular discharge
(Patel and Heldens, 2005), or the infection can be silent
(Foote et al., 2006). Replication is followed by a
leukocyte-associated viremia which enables EHV-1 to
reach internal organs. There, its replication can result in
abortion, neonatal death or nervous system disorders
(Allen and Bryans, 1986; Bryans and Allen, 1989).
Abortion can involve only one or two mares in a herd but
also abortion storms can occur on a premise, associated
with great economic losses (Allen and Bryans, 1986).
Neurological disorders have been reported with in-
creasing frequency (McMartan et al., 1995; Friday et al.,
2000; van Maanen et al., 2001; Stierstorfer et al., 2002;
van der Meulen et al., 2003a) and during an outbreak
many cases may occur with devastating effects.
Although vaccines against EHV-1 are available,
they are not fully protective (Kydd et al., 2006;
Goodman et al., 2006; van der Meulen et al., 2006a)
and outbreaks of disease may still occur (Buchner and
Mostl, 1998; Friday et al., 2000; van der Meulen et al.,
2000; Kohn et al., 2003; Goehring et al., 2006).
Therefore, there is a need for effective antiviral
chemotherapy. Antivirals need to meet several
requirements. They have to reduce viral replication
and spread in affected horses, and prevent viral
replication in in-contact animals. The drug should be
effective against isolates of EHV-1 associated with
outbreaks of abortion as well as those associated with
outbreaks of neurological disorders. Recently, it was
postulated that a variation of a single amino acid of the
DNA polymerase is strongly associated with neuro-
logical versus non-neurological disease outbreaks
(Nugent et al., 2006). This may have an implication on
the susceptibility of various isolates to anti-herpetic
compounds as many of these compounds act on the
DNA polymerase (De Clercq, 2004). Finally, the drug
should be safe and devoid of adverse effects.
Some antivirals have already been tested in vitro for
their efficacy to inhibit EHV-1 replication by means ofa plaque reduction assay, i.e. ganciclovir (Smith et al.,
1983; Rollinson and White, 1983; Rollinson, 1987),
three 20-fluoropyrimidine nucleosides (Rollinson,
1987), (S)-9-[3-hydroxy-2-phosphonylmethoxypro-
pyl]adenine or HPMPA (Field and Awan, 1990) and
the HPMPA analogue cidofovir (Gibson et al., 1992).
These compounds proved more effective than 9-
[4-hydroxy-3-hydroxymethylbut-1-yl]guanine (Boyd
et al., 1987) and penciclovir (de la Fuente et al., 1992).
For acyclovir, contradictory data have been reported.
Rollinson and White (1983) reported a 6-fold lower
EC50 than Boyd et al. (1987). Further, based on
comparison of EC50-values reported in literature,
adefovir would be the least active compound in this
series (Field and Awan, 1990). However, data of these
different studies are difficult to compare as different
isolates, cell lines and assays have been employed.
The aim of the present study was to compare the
efficacy of acyclovir, ganciclovir, cidofovir, adefovir,
PMEDAP and foscarnet against EHV-1 in vitro. Four
of these products have already been tested in vitro
while foscarnet and PMEDAP are new in this study.
Three abortigenic and three neuropathogenic isolates
of EHV-1 were included and one cell line, EEL cells,
was used. Additionally, the efficacy of the antivirals to
reduce the size of EHV-1 induced plaques was
investigated. Reduction in plaque size may be a
potential parameter for the ability of an antiviral to
inhibit cell to cell spread and, consequently to restrict
the size of macroscopic lesions in vivo.2. Materials and methods
2.1. Cells
All studies were conducted using equine embryo-
nic lung (EEL) cells. EEL cells were cultured in
growth medium (minimum essential medium (MEM)
supplemented with 100 U/ml penicillin, 0.1 mg/ml
streptomycin, 0.1 mg/ml kanamycin, 0.3 mg/ml glu-
tamine and 5% foetal calf serum). Cells were passaged
once a week.
2.2. Viruses
Six Belgian EHV-1 isolates were tested. The
isolates 94P247, 97P70 and 99P96 were isolated
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Table 1
Characteristics of the EHV-1 isolates
Viral isolate Isolated from ORF30 752a (D/N) ORF68 strainb grouping Origin
94P247 Abortion N 3 Kluisbergen (508460 north–038290 east)
97P70 Abortion N 3 Gouy-les-Pieton (508250 north–048 250 east)
99P96 Abortion N 3 Hamme (518050 north–048080 east)
97P82 Neurological disorders D 2 Nijvel (508350 north–048190 east)
99P136 Neurological disorders D 3 Kampenhout (508570 north–048340 east)
03P37 Neurological disorders D 3 Kozen (508550 north–058200 east)
a Nugent et al. (2006): ORF30 sequence variation is associated with pathogenic potential: 95% of the non-neurological isolates encoded A2254
(amino acid N752), 86% of the neurological isolates encoded G2254 (amino acid D752).
b Nugent et al. (2006): ORF68 as the primary strain grouping marker (geographical restriction of certain strain groups).from lungs of an aborted fetus in 1994, 1997 and 1999,
respectively. The isolates 97P82, 99P136 and 03P37
were isolated from the peripheral blood mononuclear
cells (PBMC) of paralytic horses in 1997, 1999 and
2003, respectively. They have been sequenced across
the ORF30 region associated with differences between
neurological versus non-neurological isolates (Nugent
et al., 2006). The abortigenic isolates were typed N752
and the neuropathogenic isolates were typed D752
(Table 1). They have also been sequenced across the
ORF68 region. The ORF68 region is used as a marker
system for distinguishing isolates into 6 common
strain groups (Nugent et al., 2006). Five of the six
isolates were located in strain group 3, while only the
isolate 97P82 was located in strain group 2 (Table 1).
Virus used for the experiments was between the fourth
and sixth passage.
2.3. Antiviral compounds
The antiviral compounds used were acyclovir
(GlaxoSmithKline, Genval, Belgium), ganciclovir
(Roche Bioscience, Palo Alto, CA, USA), cidofovir
and adefovir (Gilead Sciences, Foster City, CA, USA),
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
(PMEDAP) and foscarnet (Astra Zeneca, So¨derta¨lje,
Sweden). Compounds were dissolved in Roswell Park
Memorial Institute (RPMI)-1640 medium at a con-
centration of 1 mg/ml and stored at 4 8C until use.
2.4. Antiviral assays
EEL-cells were seeded in 24-well culture plates
(Nunc A/S) at a density of 300,000 cells/well and were
cultured at 37 8C for 24 h. Then, growth medium was
removed and cultures were infected with 40 PFU ofEHV-1/well. After 1 h, virus was removed. Cells
were rinsed twice with culture medium and overlaid
with carboxymethylcellulose 0.94% overlay medium
(Sigma) containing serial dilutions of each compound.
Infected, untreated cells served as control. Overlay
medium was removed at 50 h post inoculation and
cells were rinsed with PBS, after which the cell
monolayer was fixed with 4% paraformaldehyde and
methanol + 1% H2O2. Subsequently, an immunoper-
oxidase monolayer assay (IPMA) was performed. In
brief, polyclonal antibodies against EHV-1 (van der
Meulen et al., 2003b) were added for 1 h at 37 8C and,
after three washing steps, goat anti-horse antibodies
labeled with peroxidase (Jackson, De Pinte, Belgium)
were added for 1 h at 37 8C. Again, three washing
steps were performed, before adding the substrate
3-amino-9-ethylcarbazole (AEC) (Sigma). After
6 min of incubation at 37 8C, substrate was replaced
by acetate buffer to block enzymatic reaction.
The number of EHV-1 induced plaques was
counted for each concentration of antiviral compound
and for untreated control samples using light
microscopy (Olympus IX50). The inhibitory effect
of the antiviral compounds on plaque number was




1  ðnumber of plaquesÞ antiviralðnumber of plaquesÞ control

 100%
The concentration of each compound required to
reduce the plaque number by 50% (EC50) was
hand-calculated from the dose–response curves gen-
erated from the data.
For isolate 97P70, the effect of the antiviral
compounds on virus-induced plaque size was
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microscopy (Olympus IX50) and a digital camera
(Sony Progressive 3CCD), attached to a Macintosh
computer. Plaques were randomly selected in each
sample. At least three plaques were measured per well
to allow statistical analysis. No more than 18 plaques
were measured as this was the maximum number of
well-isolated plaques per recipient (mean number
measured per sample was 11.5  3.3). Then, the size
of the area of each plaque was determined in pixels
using Scion 1.63 (National Institutes of Health,
Bethesda, Maryland, USA) and finally, the mean
plaque size was calculated for each concentration of
antiviral.
For each experiment, three independent replicates
were performed.
2.5. Cytotoxicity assay
The effect of the antiviral compounds on the
viability of EEL cells was measured using an MTT-
based method (Hansen et al., 1989). In brief, EEL-
cells were seeded in 96-well culture plates (Nunc
A/S) at a density of 50,000 cells/well. After 24 h,
growth medium was replaced by serial dilutions of
the compounds. Untreated cells served as control.
Cells fixed with 4% paraformaldehyde were included
as background condition. At 69 h post incubation,
cells were incubated with 0.3% MTT (Sigma,
Bornem, Belgium) and were further incubated for
3 h at 37 8C to allow the production of formazan.
Then, MTT containing culture medium was removed
and 150 ml of detergent reagent (0.5% sodium
dodecyl sulphate in isopropanol) was added. Absor-Table 2
Susceptibility of 6 isolates of EHV-1 to antiviral compounds
Viral isolate EC50  S.D. (ng/ml)
Acyclovir Ganciclovir Cidofov
94P247 2.7  0.5 0.2  0.2 5.8  2
97P70 2.0  0.7 0.2  0.1 4.4  0
99P96 1.7  0.5 0.2  0.0 1.1  0
97P82 2.2  1.2 0.1  0.1 3.1  1
99P136 2.5  1.0 0.3  0.1 4.8  2
03P37 3.0  0.4 0.4  0.1 6.7  1
* Significant difference between isolate 99P96 and isolate 03P37.
+ Significant difference between the isolates 97P70 and 99P96 on one
# Significant difference between isolate 97P82 and isolate 99P136.bance was measured on a Multiskan RC (Thermo
Labsystems, Brussel, Belgium) at a wavelength
of 550 nm. Viability of cells was calculated by
following formula:
Percentage of viable cells ¼ ODt  ODd
ODc  ODd  100%
where ODt is the absorbency of cells incubated with
antiviral compounds, ODd the absorbency of the
background control and ODc the absorbency of the
untreated cells.
For each concentration of antiviral compound and
for control samples, eight wells were tested per
experiment. Three independent replicates of each
experiment were performed.
2.6. Data analysis
Statistical analysis was based on analysis of
variance (ANOVA) using SPSS (SPSS Inc., Chicago,
IL, USA).3. Results
3.1. Effect of the antiviral compounds on plaque
number
The mean EC50-values  standard deviations are
presented in Table 2. Ganciclovir proved most potent
against all isolates and inhibited viral replication with
a 50% effective concentration (EC50) of 0.1–0.4 mg/
ml. The efficacy of acyclovir (1.7–3.0 mg/ml) and the
experimental molecule PMEDAP (1.3–2.9 mg/ml)ir Adefovir PMEDAP Foscarnet
.7 4.4  1.4 1.5  0.1 11.1  2.5
.4 4.3  0.7 2.1  0.4 6.9  0.8+
.6* 2.8  1.8 1.3  1.0 6.6  1.1+
.5 4.2  2.0 2.0  0.7 7.9  2.6#
.1 5.6  1.2 2.3  0.6 16.2  2.6+,#
.2* 3.8  1.8 2.9  0.2 15.8  3.6+
hand, and the isolates 99P136 and 03P37 on the other hand.
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Fig. 1. The effect of antivirals on the size of virus-induced plaques. All products were able to reduce the plaque size significantly. The data
represent the mean + S.D. of three independent experiments. Significant difference between test sample and untreated control (LSD, *P < 0.05)
(0.01 < *P < 0.05; 0.001 < **P < 0.01; ***P < 0.001).
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a concentration of 2.8–5.6 mg/ml. For all four
compounds, there was no difference in susceptibility
between the various isolates. The efficacy of cidofovir
(3.1–6.7 mg/ml) was comparable with the efficacy of
adefovir, except for isolate 99P96. This isolate
displayed a clearly lower EC50 for cidofovir
(1.1 mg/ml). Foscarnet was the least effective
compound (6.6–11.1 mg/ml) and susceptibility
showed a marked variation among isolates. The
isolates 99P136 and 03P37 were clearly less
susceptible to foscarnet than the other isolates
(15.8 and 16.2 mg/ml).
3.2. Effect of the antiviral compounds on plaque
size
As a complementary parameter of assessing the
efficacy of the antiviral compounds, the mean plaque
size (in pixels) of the antiviral treated relative to the
size of plaques in untreated cultures was determined
for isolate 97P70 (Fig. 1).
It is known that marked differences may occur in
plaque size when EHV-1 is grown in vitro. Therefore,
data obtained in the plaque size assay were subjected
to an F-test to examine whether the variation in
plaque size between samples was significantly
different from the variation in plaque size within a
sample (95% confidence interval). Or, in other
words, the F-test was used to answer the question
whether variation in plaque size was merely an
artefact or whether it was related to the use of
antiviral drugs. It was found that all compounds
exhibited a significant effect on plaque size. Using a
post hoc LSD-test it was demonstrated that the
reduction in plaque size was significant for all
antiviral compounds when compared to the untreated
control (95% confidence interval).
Acyclovir reduced plaque size significantly at a
concentration of 2 mg/ml or higher, ganciclovir at a
concentration of 0.1 mg/ml or higher and PMEDAP
at a concentration of 1 mg/ml or higher. Cidofovir,
adefovir and foscarnet reduced plaque size sig-
nificantly at respective concentrations of 0.125, 0.25
and 2 mg/ml or higher. The latter drugs are thus
more effective (4-, 16- and 40-fold, respectively) in
reducing plaque size than in reducing plaque
number.3.3. Effect of the antiviral compounds on the
viability of EEL-cells
None of the compounds resulted in a significant
decrease of viability of uninfected EEL cells at
concentrations that were able to exert an antiviral
effect. Acyclovirwas toxic at a concentration of 320 mg/
ml or more, ganciclovir at a concentration of more than
500 mg/ml, cidofovir at a concentration of 500 mg/ml or
more, foscarnet at a concentration of 500 mg/ml or
more, adefovir at a concentration of 80 mg/ml or more
and PMEDAP at a concentration of 320 mg/ml or more
(ANOVA, LSD, P > 0.03).4. Discussion
The present study was conducted to compare the
efficacy of a selection of anti-herpetic drugs against
six isolates of EHV-1 in vitro. Based on the EC50-value
for inhibition of plaque formation, ganciclovir
emerged as the most potent compound against all
six isolates. Acyclovir and PMEDAP were approxi-
mately 10-fold less effective and adefovir was
approximately 20-fold less effective than ganciclovir.
For cidofovir and foscarnet, the efficacy was isolate-
dependent. Isolate 99P96 was more susceptible to
cidofovir as it had a lower EC50-value than the other
isolates. On the other hand, the isolates 03P37 and
99P136 were clearly less susceptible to foscarnet in
comparison with the other isolates. There was no
correlation between the susceptibility of an isolate to
foscarnet and whether it was isolated from an outbreak
of abortion or an outbreak of neurological disorders.
Also, there was no correlation with the location or with
the year of isolation. As foscarnet is the least potent
compound against EHV-1 and as there is a great
difference between various isolates in their suscept-
ibility to this drug, foscarnet has no potential as a drug
for the treatment of infected horses.
Based on the results of sequencing across the
ORF30 region, we were not able to detect differences
in susceptibility between non-neurological and neu-
rological isolates. However, there are other ways to
distinguish isolates which may have an influence on
the susceptibility to antivirals. For example, isolates
can also be distinguished in six strain groups by using
ORF68 as strain group marker (Nugent et al., 2006).
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ORF68, as all our isolates, except one, were assigned
to one group. Also possible variations in ORF18 may
be interesting to study as this gene encodes the
processivity subunit of the DNA polymerase (Telford
et al., 1998).
Antiviral compounds not only reduce the number
of herpesvirus-induced plaques, they also contribute in
the reduction of plaque size (Mikloska and Cunning-
ham, 2001; Jenssen et al., 2004; van der Meulen et al.,
2006b). We found that all compounds were able to
significantly reduce EHV-1 induced plaque size. Thus,
plaque size is a useful and complementary means of
assessing antiviral efficacy. The lowest concentration
that was able to significantly reduce plaque size
approached the EC50 for acyclovir, ganciclovir and
PMEDAP, while the other products were able to
reduce plaque size at concentrations significantly
lower than their EC50. The most remarkable effect was
seen for cidofovir. Cidofovir was 40-fold more
effective in reducing plaque size than in reducing
the plaque number. The relevance of this finding in
view of treatment of horses against EHV-1 induced
disease remains to be determined. However, as already
speculated by Mikloska and Cunningham (2001), a
significant reduction of plaque size in vitro may be a
potential parameter for the ability of an antiviral agent
to restrict the size of virus-induced lesions in vivo.
Although the acyclic nucleoside analogues acy-
clovir and ganciclovir share a similar requirement for
enzymatic phosphorylation, the relative high efficacy
of ganciclovir, compared to acyclovir, is noteworthy.
The better activity of ganciclovir may be related to a
more efficient phosphorylation of ganciclovir to its 50-
monophosphate form by the EHV-1 thymidine kinase,
a more efficient activation of the 50-monophosphate
form to the triphosphate metabolite by cellular kinases
(Smee et al., 1985; De Clercq, 1993) or a more
efficient inhibition of the viral polymerase by
ganciclovir 50-triphosphate than by acyclovir 50-
triphosphate (Smee et al., 1985; Mar et al., 1985).
Also for the acyclic nucleoside analogues adefovir and
PMEDAP, the difference in efficacy is remarkable.
The study of Kramata and Downey (1999) suggests
that differences in inhibition of cellular DNA
synthesis may be explained by different intracellular
ratios of the analogue diphosphates to their corre-
sponding deoxynucleoside triphosphates and differentaffinities of DNA polymerases for the nucleotide
analogue diphosphates.
From our results, we can conclude that ganciclovir
displays the best overall activity against EHV-1
infection in vitro, without affecting cell viability.
However, due to the high cost price, there is no direct
clinical application possible. Therefore, acyclovir
seems a more valuable candidate for antiviral therapy
against EHV-1 infection in horses. As acyclovir is
from patent since 1997 and generic alternatives are
available, it seems attractive to use this drug for the
treatment of horses during an outbreak. Previous
studies (Wilkins et al., 2005) indicated that twice
daily IV infusions of acyclovir (10 mg/kg) results in
plasma concentrations above EC50-levels during the
entire treatment interval. However, the EC50-value
reported in their study was 0.3 mg/ml, which is 10-
fold lower than the one we found. Our EC50-value
implies that the infusion should be given much more
frequently, i.e. 8 times per day, to exceed concentra-
tions greater than 1.7–3.0 mg/ml for the entire
treatment interval. This limits the clinical application
due to the high costs and practical administration
during an outbreak. Oral administration of acyclovir
may be an alternative. However, the bioavailability of
orally administered acyclovir is a restriction. Bentz
et al. (2006) reported a bioavailability of only 2.8%
resulting in low plasma concentrations, inadequate to
expect any clinically relevant antiviral efficacy. The
oral prodrug of acyclovir, valacyclovir, may be more
effective due to its higher bioavailability (Ormrod
and Goa, 2000). Also the experimental compound
PMEDAP can be a useful antiviral in the future.
Although cidofovir is not highly efficient in reducing
plaque number, it is able to significantly reduce
plaque size at very low concentrations. As foscarnet
is the least potent compound against EHV-1 and as
there is a great difference between various isolates in
their susceptibility to this drug, foscarnet has no
potential as a drug for the treatment of infected
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